X4 Pharmaceuticals, Inc. (XFOR) has a negative trailing P/E of -5.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 25.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -17.73%, forward earnings yield 3.93%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.5 | -0.04 | -2.00 | 0.00 | - |
| 2017 | -0.1 | 0.00 | 0.07 | 0.00 | - |
| 2018 | 0.0 | 0.00 | -0.09 | 0.00 | - |
| 2019 | -2.3 | 0.02 | 0.95 | 0.00 | - |
| 2020 | -2.1 | 0.06 | 1.77 | 43.03 | - |
| 2021 | -0.7 | -0.02 | 0.92 | 0.00 | - |
| 2022 | -0.7 | 0.01 | 0.85 | 0.00 | - |
| 2023 | -1.5 | 0.02 | 2.92 | 0.00 | - |
| 2024 | -3.9 | 0.06 | 6.66 | 57.69 | - |
| 2025 | -2.1 | 0.03 | 0.91 | 4.82 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-4.38 | $0.00 | $-22.98M | - |
| 2017 | $-54.57 | $0.00 | $-33.88M | - |
| 2018 | $-79.10 | $3.5M | $-43.02M | -1229.2% |
| 2019 | $-4.63 | $0.00 | $-56.6M | - |
| 2020 | $-3.09 | $3M | $-62.13M | -2071% |
| 2021 | $-3.99 | $0.00 | $-88.7M | - |
| 2022 | $-1.52 | $0.00 | $-93.87M | - |
| 2023 | $-0.57 | $0.00 | $-101.17M | - |
| 2024 | $-0.19 | $2.56M | $-37.45M | -1464.6% |
| 2025 | $-1.87 | $35.11M | $-79.2M | -225.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.87 | $-1.04 – $-0.70 | $8.03M | $5.85M – $10.22M | 2 |
| 2027 | $-0.83 | $-1.04 – $-0.60 | $6.9M | $6.79M – $7.01M | 2 |
| 2028 | $-0.70 | $-1.16 – $-0.24 | $126.85M | $106.61M – $154M | 2 |
| 2029 | $0.17 | $0.13 – $0.21 | $330.1M | $277.44M – $400.74M | 1 |
| 2030 | $1.86 | $1.47 – $2.37 | $712.45M | $598.79M – $864.92M | 1 |
